NeuroQuest Inc.

NeuroQuest develops OTC & Rx drugs from bioactives for treatment of nerve pain. Products are being prepared for Canada, US & China.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Halifax, NS, Canada
  • Currency USD
  • Founded January 2009
  • Employees 7
  • Website neuroquest.ca

Company Summary

NeuroQuest Inc. is a Canadian biotechnology company focused on developing prescription drugs from enhanced chemical modifications to natural bioactives for the treatment of neurological diseases. NeuroQuest is conducting a neuropathic pain topical drug development program with drugs being prepared for Canada, USA and China.

NeuroQuest is researching of a class of small-molecule, lipophilic compounds that demonstrate multiple mechanisms of action on nerve receptors. NeuroQuest’s lead compounds are PN-34 (native bioactive) and NQ1123 (new chemical entity) are safe, effective, fast-acting, non-numbing, patent-protected leads for neuropathic pain and other nerve conditions.

A Canadian natural product license is expected for PN-34 within 15 months. A Canadian license will be immediately leveraging into a partnership with a Chinese Pharma company for sales in China. A US FDA pre-IND meeting is scheduled for 2016.

Team

  • Robert Cervelli
    President, CEO

    Robert has been a serial entrepreneur in N. American life sciences for over 25 yrs. Robert has founded, or co-founded, biotech companies developing diagnostics, cancer therapy, vaccine enhancement technology, neurological drug discovery and consumer health products.

  • YC Lee
    Managing Director - Concept to Clinic Inc. (Joint Venture partner)

    Dr. Lee has over 22 yrs of extensive pharma experience. Dr. Lee was a co-founder/CEO of Xphase Pharma. Dr. Lee became Sen Dir at PharmEng in 2006 and was Dir of Analytical Dev at Patheon. Dr. Lee held senior positions during 11 years at Eli Lilly Canada.

  • Dr. Alex McLellan
    Chief Scientific Officer

    Alex has 10 yrs experience R&D, including in vitro, in vivo and human clinical trials and 10 yrs clinical and new product dev.

  • Dr. Albert Agro
    Chief Medical Officer, Concept to Clinic (joint venture partner)

    Dr. Agro has 19 yrs of exp. In 1996 he joined Boehringer Ingelheim as Sen Clinical Scientist in CNS/Inflammation and in 1998, joined Bayer as Dir. Cardiopulmonary Res. In 2000, Dr Agro re-joined Boehringer Ingelheim.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free